STOCK TITAN

Day One to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) will present at the 21st Annual Needham Virtual Healthcare Conference on April 13 at 3:45 p.m. ET. The event provides an opportunity for management to discuss the company's advancements in developing targeted therapies for life-threatening diseases, particularly pediatric cancer. A live audio webcast of the presentation will be accessible via the company's website, with an archived replay available for 30 days post-event.

Founded to address unmet needs in pediatric cancer treatment, Day One focuses on innovative cancer drug development.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET.

A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for patients of all ages with life-threatening diseases. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor and the pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com


FAQ

When will Day One Biopharmaceuticals present at the Needham Virtual Healthcare Conference?

Day One Biopharmaceuticals will present on April 13, 2022, at 3:45 p.m. ET.

How can I access the Day One Biopharmaceuticals conference presentation?

You can access the live audio webcast through the Events & Presentations section of Day One Biopharmaceuticals' website.

What is the focus of Day One Biopharmaceuticals?

Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases, especially in pediatric cancer.

What is the ticker symbol for Day One Biopharmaceuticals?

The ticker symbol for Day One Biopharmaceuticals is DAWN.

What is the lead product candidate of Day One Biopharmaceuticals?

The lead product candidate of Day One Biopharmaceuticals is tovorafenib (DAY101), an investigational pan-RAF kinase inhibitor.

Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

DAWN Latest News

DAWN Stock Data

1.50B
100.85M
17.49%
77.81%
16.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE